TAVI术后抗凝联合或不联合氯吡格雷
该随机试验纳入接受TAVI且因适应症正在口服抗凝的患者,1:1随机分为不联合氯吡格雷组与联合氯吡格雷3个月组。主要终点为12个月内所有出血及非操作相关出血。单用抗凝组出血发生率21.7%,联合组34.6%(RR 0.63,95%CI 0.43-0.90,P=0.01);非操作相关出血分别为21.7%与34.0%(RR 0.64,95%CI 0.44-0.92,P=0.02)。次要复合终点1发生率单用组31.2% vs 联合组45.5%(差异-14.3个百分点,非劣效95%CI -25.0至-3.6;优效性RR 0.69,95%CI 0.51-0.92)。结论:单用口服抗凝较联合氯吡格雷降低1个月或1年严重出血发生率。
要点
- 接受口服抗凝的TAVI患者,不联合氯吡格雷组12个月所有出血发生率21.7%(34/157),联合氯吡格雷3个月组34.6%(54/156),RR 0.63(95%CI 0.43-0.90,P=0.01)。
- 非操作相关出血单用抗凝组21.7%(34例) vs 联合组34.0%(53例),RR 0.64(95%CI 0.44-0.92,P=0.02)。
- 大多数出血发生在第一个月且为轻微出血,多数出血位于TAVI穿刺部位。
- 次要复合终点1(心血管死亡、非操作相关出血、卒中或心肌梗死)单用组31.2%(49例) vs 联合组45.5%(71例),差异-14.3个百分点(非劣效95%CI -25.0至-3.6),优效性RR 0.69(95%CI 0.51-0.92)。
- 次要复合终点2(心血管死亡、缺血性卒中或心肌梗死)单用组13.4%(21例) vs 联合组17.3%(27例),差异-3.9个百分点(非劣效95%CI -11.9至4.0),优效性RR 0.77(95%CI 0.46-1.31)。
适用人群与场景
- 接受TAVI且因适当适应症正在口服抗凝的患者。
处置流程与药物剂量
- TAVI术前按1:1随机分配为不联合氯吡格雷或联合氯吡格雷3个月。
研究设计与关键结果
- 随机试验:接受TAVI且口服抗凝的患者,不联合氯吡格雷组157例 vs 联合氯吡格雷3个月组156例。
- 主要终点:12个月所有出血单用抗凝组21.7%(34/157) vs 联合组34.6%(54/156),RR 0.63(95%CI 0.43-0.90,P=0.01);非操作相关出血单用组21.7%(34例) vs 联合组34.0%(53例),RR 0.64(95%CI 0.44-0.92,P=0.02)。
- 大多数出血发生在第一个月且为轻微出血,多数出血位于TAVI穿刺部位。
- 次要复合终点1(心血管死亡、非操作相关出血、卒中或心肌梗死)单用组31.2%(49例) vs 联合组45.5%(71例),差异-14.3个百分点(非劣效95%CI -25.0至-3.6),优效性RR 0.69(95%CI 0.51-0.92)。
- 次要复合终点2(心血管死亡、缺血性卒中或心肌梗死)单用组13.4%(21例) vs 联合组17.3%(27例),差异-3.9个百分点(非劣效95%CI -11.9至4.0),优效性RR 0.77(95%CI 0.46至1.31)。
证据类型、等级与局限
- 证据类型:随机试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于接受TAVI且正在口服抗凝的患者,不联合氯吡格雷较联合氯吡格雷3个月降低1个月或1年严重出血发生率。
指南或共识出处
- POPular TAVI,EU Clinical Trials Register编号2013-003125-28,ClinicalTrials.gov编号NCT02247128;资助方:Netherlands Organization for Health Research and Development。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The roles of anticoagulation alone or with an antiplatelet agent after transcatheter aortic-valve implantation (TAVI) have not been well studied.
METHODS: We performed a randomized trial of clopidogrel in patients undergoing TAVI who were receiving oral anticoagulation for appropriate indications. Patients were assigned before TAVI in a 1:1 ratio not to receive clopidogrel or to receive clopidogrel for 3 months. The two primary outcomes were all bleeding and non-procedure-related bleeding over a period of 12 months. Procedure-related bleeding was defined as Bleeding Academic Research Consortium type 4 severe bleeding, and therefore most bleeding at the puncture site was counted as non-procedure-related. The two secondary outcomes were a composite of death from cardiovascular causes, non-procedure-related bleeding, stroke, or myocardial infarction at 12 months (secondary composite 1) and a composite of death from cardiovascular causes, ischemic stroke, or myocardial infarction (secondary composite 2), both tested for noninferiority (noninferiority margin, 7.5 percentage points) and superiority.
RESULTS: Bleeding occurred in 34 of the 157 patients (21.7%) receiving oral anticoagulation alone and in 54 of the 156 (34.6%) receiving oral anticoagulation plus clopidogrel (risk ratio, 0.63; 95% confidence interval [CI], 0.43 to 0.90; P = 0.01); most bleeding events were at the TAVI access site. Non-procedure-related bleeding occurred in 34 patients (21.7%) and in 53 (34.0%), respectively (risk ratio, 0.64; 95% CI, 0.44 to 0.92; P = 0.02). Most bleeding occurred in the first month and was minor. A secondary composite 1 event occurred in 49 patients (31.2%) receiving oral anticoagulation alone and in 71 (45.5%) receiving oral anticoagulation plus clopidogrel (difference, -14.3 percentage points; 95% CI for noninferiority, -25.0 to -3.6; risk ratio, 0.69; 95% CI for superiority, 0.51 to 0.92). A secondary composite 2 event occurred in 21 patients (13.4%) and in 27 (17.3%), respectively (difference, -3.9 percentage points; 95% CI for noninferiority, -11.9 to 4.0; risk ratio, 0.77; 95% CI for superiority, 0.46 to 1.31).
CONCLUSIONS: In patients undergoing TAVI who were receiving oral anticoagulation, the incidence of serious bleeding over a period of 1 month or 1 year was lower with oral anticoagulation alone than with oral anticoagulation plus clopidogrel. (Funded by the Netherlands Organization for Health Research and Development; POPular TAVI EU Clinical Trials Register number, 2013-003125-28; ClinicalTrials.gov number, NCT02247128.).
参考来源
- Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med. 2020. PMID: 32223116. doi:10.1056/NEJMoa1915152
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。